Psoriatic arthritis
ABSTRACT Although there is still some controversy about the existence of psoriatic arthritis (PsA) as a specific form of inflammatory arthritis associated with psoriasis, epidemiological and clinical studies support the unique features of PsA. Because of lack of diagnostic or classification criteria...
Gespeichert in:
Veröffentlicht in: | Dermatologic therapy 2009-01, Vol.22 (1), p.40-55 |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 55 |
---|---|
container_issue | 1 |
container_start_page | 40 |
container_title | Dermatologic therapy |
container_volume | 22 |
creator | Gladman, Dafna D. |
description | ABSTRACT
Although there is still some controversy about the existence of psoriatic arthritis (PsA) as a specific form of inflammatory arthritis associated with psoriasis, epidemiological and clinical studies support the unique features of PsA. Because of lack of diagnostic or classification criteria, the disease has been thought of as uncommon. New classification criteria should facilitate case definition of PsA. Over the past several decades, it has become clear that the disease leads to serious disability and even increased mortality. Traditional medications have not been effective in preventing the progression of joint damage. New medications, including biologics, have emerged with potential to controlling the inflammation and arresting the progression of joint damage. |
doi_str_mv | 10.1111/j.1529-8019.2008.01215.x |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66940235</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66940235</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4815-fc801c6ee5b0fddb7df5e522c26d66c4f957f8a6c23da15d712ad5712ee57213</originalsourceid><addsrcrecordid>eNqNkMFPwjAUhxujEURP3g0nb5ttt3brwYMBASNRDiQaLy-l7WJxOGxHhP_ezhG82kP7kn7fe3k_hPoExyScm2VMGBVRjomIKcZ5jAklLN4eoe7h4zjUieARpoJ30Jn3SxwokZBT1CGCUsoI76LLma-clbVVfenqd2dr68_RSSFLby72bw_NR_fzwSSaPo8fBnfTSKU5YVGhwhjFjWELXGi9yHTBDKNUUa45V2khWFbkkiuaaEmYzgiVmoU7GBklSQ9dt23XrvraGF_DynplylJ-mmrjgXORYpqwAOYtqFzlvTMFrJ1dSbcDgqHJA5bQrA3N2tDkAb95wDaoV_sZm8XK6D9xH0AAblvg25Zm9-_GMJxPmir4UetbX5vtwZfuA3iWZAxensaAZ-l49Pb4Cjz5AdrsfAY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66940235</pqid></control><display><type>article</type><title>Psoriatic arthritis</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Gladman, Dafna D.</creator><creatorcontrib>Gladman, Dafna D.</creatorcontrib><description>ABSTRACT
Although there is still some controversy about the existence of psoriatic arthritis (PsA) as a specific form of inflammatory arthritis associated with psoriasis, epidemiological and clinical studies support the unique features of PsA. Because of lack of diagnostic or classification criteria, the disease has been thought of as uncommon. New classification criteria should facilitate case definition of PsA. Over the past several decades, it has become clear that the disease leads to serious disability and even increased mortality. Traditional medications have not been effective in preventing the progression of joint damage. New medications, including biologics, have emerged with potential to controlling the inflammation and arresting the progression of joint damage.</description><identifier>ISSN: 1396-0296</identifier><identifier>EISSN: 1529-8019</identifier><identifier>DOI: 10.1111/j.1529-8019.2008.01215.x</identifier><identifier>PMID: 19222516</identifier><language>eng</language><publisher>Malden, USA: Blackwell Publishing Inc</publisher><subject>Arthritis, Psoriatic - classification ; Arthritis, Psoriatic - drug therapy ; Arthritis, Psoriatic - mortality ; Arthritis, Psoriatic - physiopathology ; Biological Products - immunology ; Biological Products - therapeutic use ; Clinical Trials as Topic ; Disease Progression ; epidemiology ; Humans ; Joints - physiopathology ; Prognosis ; psoriatic arthritis ; Quality of Life ; Remission Induction - methods ; treatment</subject><ispartof>Dermatologic therapy, 2009-01, Vol.22 (1), p.40-55</ispartof><rights>2009 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4815-fc801c6ee5b0fddb7df5e522c26d66c4f957f8a6c23da15d712ad5712ee57213</citedby><cites>FETCH-LOGICAL-c4815-fc801c6ee5b0fddb7df5e522c26d66c4f957f8a6c23da15d712ad5712ee57213</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1529-8019.2008.01215.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1529-8019.2008.01215.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19222516$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gladman, Dafna D.</creatorcontrib><title>Psoriatic arthritis</title><title>Dermatologic therapy</title><addtitle>Dermatol Ther</addtitle><description>ABSTRACT
Although there is still some controversy about the existence of psoriatic arthritis (PsA) as a specific form of inflammatory arthritis associated with psoriasis, epidemiological and clinical studies support the unique features of PsA. Because of lack of diagnostic or classification criteria, the disease has been thought of as uncommon. New classification criteria should facilitate case definition of PsA. Over the past several decades, it has become clear that the disease leads to serious disability and even increased mortality. Traditional medications have not been effective in preventing the progression of joint damage. New medications, including biologics, have emerged with potential to controlling the inflammation and arresting the progression of joint damage.</description><subject>Arthritis, Psoriatic - classification</subject><subject>Arthritis, Psoriatic - drug therapy</subject><subject>Arthritis, Psoriatic - mortality</subject><subject>Arthritis, Psoriatic - physiopathology</subject><subject>Biological Products - immunology</subject><subject>Biological Products - therapeutic use</subject><subject>Clinical Trials as Topic</subject><subject>Disease Progression</subject><subject>epidemiology</subject><subject>Humans</subject><subject>Joints - physiopathology</subject><subject>Prognosis</subject><subject>psoriatic arthritis</subject><subject>Quality of Life</subject><subject>Remission Induction - methods</subject><subject>treatment</subject><issn>1396-0296</issn><issn>1529-8019</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkMFPwjAUhxujEURP3g0nb5ttt3brwYMBASNRDiQaLy-l7WJxOGxHhP_ezhG82kP7kn7fe3k_hPoExyScm2VMGBVRjomIKcZ5jAklLN4eoe7h4zjUieARpoJ30Jn3SxwokZBT1CGCUsoI76LLma-clbVVfenqd2dr68_RSSFLby72bw_NR_fzwSSaPo8fBnfTSKU5YVGhwhjFjWELXGi9yHTBDKNUUa45V2khWFbkkiuaaEmYzgiVmoU7GBklSQ9dt23XrvraGF_DynplylJ-mmrjgXORYpqwAOYtqFzlvTMFrJ1dSbcDgqHJA5bQrA3N2tDkAb95wDaoV_sZm8XK6D9xH0AAblvg25Zm9-_GMJxPmir4UetbX5vtwZfuA3iWZAxensaAZ-l49Pb4Cjz5AdrsfAY</recordid><startdate>200901</startdate><enddate>200901</enddate><creator>Gladman, Dafna D.</creator><general>Blackwell Publishing Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200901</creationdate><title>Psoriatic arthritis</title><author>Gladman, Dafna D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4815-fc801c6ee5b0fddb7df5e522c26d66c4f957f8a6c23da15d712ad5712ee57213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Arthritis, Psoriatic - classification</topic><topic>Arthritis, Psoriatic - drug therapy</topic><topic>Arthritis, Psoriatic - mortality</topic><topic>Arthritis, Psoriatic - physiopathology</topic><topic>Biological Products - immunology</topic><topic>Biological Products - therapeutic use</topic><topic>Clinical Trials as Topic</topic><topic>Disease Progression</topic><topic>epidemiology</topic><topic>Humans</topic><topic>Joints - physiopathology</topic><topic>Prognosis</topic><topic>psoriatic arthritis</topic><topic>Quality of Life</topic><topic>Remission Induction - methods</topic><topic>treatment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gladman, Dafna D.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Dermatologic therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gladman, Dafna D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Psoriatic arthritis</atitle><jtitle>Dermatologic therapy</jtitle><addtitle>Dermatol Ther</addtitle><date>2009-01</date><risdate>2009</risdate><volume>22</volume><issue>1</issue><spage>40</spage><epage>55</epage><pages>40-55</pages><issn>1396-0296</issn><eissn>1529-8019</eissn><abstract>ABSTRACT
Although there is still some controversy about the existence of psoriatic arthritis (PsA) as a specific form of inflammatory arthritis associated with psoriasis, epidemiological and clinical studies support the unique features of PsA. Because of lack of diagnostic or classification criteria, the disease has been thought of as uncommon. New classification criteria should facilitate case definition of PsA. Over the past several decades, it has become clear that the disease leads to serious disability and even increased mortality. Traditional medications have not been effective in preventing the progression of joint damage. New medications, including biologics, have emerged with potential to controlling the inflammation and arresting the progression of joint damage.</abstract><cop>Malden, USA</cop><pub>Blackwell Publishing Inc</pub><pmid>19222516</pmid><doi>10.1111/j.1529-8019.2008.01215.x</doi><tpages>16</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1396-0296 |
ispartof | Dermatologic therapy, 2009-01, Vol.22 (1), p.40-55 |
issn | 1396-0296 1529-8019 |
language | eng |
recordid | cdi_proquest_miscellaneous_66940235 |
source | MEDLINE; Access via Wiley Online Library |
subjects | Arthritis, Psoriatic - classification Arthritis, Psoriatic - drug therapy Arthritis, Psoriatic - mortality Arthritis, Psoriatic - physiopathology Biological Products - immunology Biological Products - therapeutic use Clinical Trials as Topic Disease Progression epidemiology Humans Joints - physiopathology Prognosis psoriatic arthritis Quality of Life Remission Induction - methods treatment |
title | Psoriatic arthritis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-31T10%3A44%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Psoriatic%20arthritis&rft.jtitle=Dermatologic%20therapy&rft.au=Gladman,%20Dafna%20D.&rft.date=2009-01&rft.volume=22&rft.issue=1&rft.spage=40&rft.epage=55&rft.pages=40-55&rft.issn=1396-0296&rft.eissn=1529-8019&rft_id=info:doi/10.1111/j.1529-8019.2008.01215.x&rft_dat=%3Cproquest_cross%3E66940235%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=66940235&rft_id=info:pmid/19222516&rfr_iscdi=true |